Related Experiment Video
Updated: Jun 6, 2026
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
Rational design of inhibitors and activity-based probes targeting Clostridium difficile virulence factor TcdB
Aaron W Puri1, Patrick J Lupardus, Edgar Deu
1Department of Chemical and Systems Biology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, California 94305, USA.
Abstract:
Clostridium difficile is a leading cause of nosocomial infections. The major virulence factors of this pathogen are the multi-domain toxins TcdA and TcdB. These toxins contain a cysteine protease domain (CPD) that autoproteolytically releases a cytotoxic effector domain upon binding intracellular inositol hexakisphosphate. Currently, there are no known inhibitors of this protease. Here, we describe the rational design of covalent small molecule inhibitors of TcdB CPD. We identified compounds that inactivate TcdB holotoxin function in cells and solved the structure of inhibitor-bound protease to 2.0 Å. This structure reveals the molecular basis of CPD substrate recognition and informed the synthesis of activity-based probes for this enzyme. The inhibitors presented will guide the development of therapeutics targeting C. difficile, and the probes will serve as tools for studying the unique activation mechanism of bacterial toxin CPDs.
Insights
Researchers designed small molecule inhibitors targeting Clostridium difficile toxin B
Area of Science:
- Microbiology
- Biochemistry
- Drug Discovery
Background:
- Clostridium difficile is a major cause of hospital-acquired infections.
- Toxins TcdA and TcdB are key virulence factors, featuring a cysteine protease domain (CPD).
- The CPD autoproteolytically releases a cytotoxic effector domain, crucial for toxicity.
Purpose of the Study:
- To rationally design covalent small molecule inhibitors of the TcdB CPD.
- To develop novel therapeutic strategies against C. difficile infections.
Main Methods:
- Rational design of small molecule inhibitors.
- Biochemical assays to assess TcdB holotoxin inactivation.
- X-ray crystallography to determine the structure of inhibitor-bound CPD.
Main Results:
- Identified potent covalent inhibitors of TcdB CPD.
- Determined the 2.0 Å crystal structure of the inhibitor-bound protease.
- Elucidated the molecular basis of substrate recognition by CPD.
- Synthesized activity-based probes for studying CPD activation.
Conclusions:
- The developed inhibitors show potential for therapeutic development against C. difficile.
- The activity-based probes will aid in understanding bacterial toxin CPD activation mechanisms.
